News Archive

Leading experts recently explored how generative AI could revolutionize clinical research through automated documentation and enhanced trial efficiency. Their findings, published in JACC: Advances, outline crucial steps for successful AI integration while addressing technical, ethical, and regulatory challenges to ensure more accessible and effective research outcomes.

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit in taking metformin at a titrated dosage of 1,500 mg per day for 14 days for the treatment of mild-to-moderate COVID-19 symptoms.

A new publication developed in collaboration by CTTI, the Duke Clinical Research Institute (DCRI), the Duke Margolis Institute for Health Policy, and Protas published in Trials highlights the current barriers to clinical trial transformation, areas of improvement, and actions needed to transform clinical evidence generation in the United States to better align with clinical care demands. A modern clinical trial infrastructure should prioritize trial accessibility, answer relevant study questions reliably, respond to public health emergencies rapidly, and more.

New evidence and results from eight studies based on data from the IPF-PRO/ILD-PRO Registry was shared by the Duke Clinical Research Institute (DCRI) and its collaborators at the American Tho

After decades of decline, heart failure mortality is climbing, with a dramatic rise in heart failure deaths among younger adults. The number of people dying from heart failure in the United States went down steadily from 1999 to 2009. However, progress made in treating heart failure began unraveling from 2009 to 2012 when heart failure-related mortality rates plateaued, according to a study led by Duke University School of Medicine.

An antibiotic that has shown effectiveness for bacterial pneumonia also appears successful in fighting methicillin-resistant staph infections, reports a team led by Duke Health. The drug, ceftobiprole, showed similar benefit when tested against the antibiotic daptomycin to treat complicated Staphylococcus aureus bacterial infections. If approved by the FDA, ceftobiprole could provide another line of defense against a common and often deadly bacterial infection.

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no clinical benefit to taking fluticasone furoate for treatment of mild-to-moderate COVID-19 symptoms.

Despite numerical improvements in mortality, hospitalizations and exercise ability, data did not reach the pre-specified level of statistical significance.

Newly published research led by the Pediatrix Medical Group and the Duke Clinical Research Institute’s Rachel Greenberg, MD, MB, MHS, assessed the impact of COVID-19 on pregnant women and infants admitted to the neonatal intensive care unit (NICU). It is believed to be the largest study evaluating the prevalence of COVID-19 within a neonatal population and associated hospital outcomes.

Results from a Duke Clinical Research Institute study that were recently published in JAMA Network Open expand the depth of understanding of how dexamethasone can improve outcomes among patients ho